Navigation Links
First Patients Enrolled in the Access-Europe Study of The MitraClip(R) Therapy
Date:4/6/2009

European Post Market Observational Study Intended to Collect Data to Demonstrate the Clinical and Health Economic Benefits of the MitraClip(R) Therapy for Patients with Mitral Regurgitation

MENLO PARK, Calif., April 6 /PRNewswire/ -- Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, announced today the first enrollment in the ACCESS-Europe study, a post-market observational study of the MitraClip(R) therapy in Europe. The MitraClip(R) system is the first commercially available treatment option for non-surgical mitral valve repair for patients suffering from the effects of functional and degenerative mitral regurgitation (MR).

MR affects millions of people worldwide and is the most common type of heart valve insufficiency in Europe and the United States. In Europe, similar to the US, there are approximately 250,000 new diagnoses of significant MR each year; however, only 20 percent or approximately 50,000 of these patients undergo surgery each year. Non-surgical patients and many of the higher risk surgical patients continue to be affected by the chronic volume overload caused by MR, which requires the heart to work harder, which may lead to heart failure and hospitalization.

The first patients were enrolled in ACCESS-Europe by a team led by Professor Corrado Tamburino, M.D.; Gian Paolo Ussia, M.D.; Salvatore Scandura, M.D.; and Sarah Mangiafico, M.D. at Ferrarotto Hospital at Catania University in Sicily, Italy.

"ACCESS-Europe will provide important clinical care and health economic information about the MitraClip(R) therapy," said Professor Tamburino, chair of cardiology, cardiology department, cardiac catheterization and interventional cardiology, Ferrarotto Hospital, University of Catania, Sicily. "This data will allow us to further understand the benefits of the MitraClip(R) therapy for patients with mitral regurgitation and the health economic benefits of a less invasive alternative for patients suffering from MR."

The ACCESS-Europe study will evaluate the MitraClip(R) therapy in the continuum of care available to patients with MR. Patients will be evaluated at baseline through 12 months after enrollment. As many as 20 institutions within Europe will participate and up to 300 patients treated with the MitraClip(R) device will be enrolled. In addition, information will be collected in two comparator groups, one which includes medically managed heart failure patients with MR and another which includes patients who are undergoing mitral valve surgery for MR.

"Initiating enrollment in ACCESS-Europe is another important milestone for Evalve and the MitraClip therapy," said Ferolyn Powell, president and chief executive officer of Evalve. "This study is designed to provide meaningful clinical and health economic information building on the important foundation of data already generated in the US. The early experience in Europe has been primarily the treatment of patients who are either non-surgical candidates, or higher risk surgical patients, with functional MR."

Evalve received CE Mark approval for the MitraClip(R) system last year, and has worked with hospitals across Europe to establish training programs in support of the European roll out. Patients have been treated in Italy, Germany, the United Kingdom, the Netherlands and Switzerland.

About the MitraClip(R) Procedure

Percutaneous mitral repair with Evalve's MitraClip(R) device is performed by physicians in the catheterization laboratory. The heart beats normally during the procedure, and therefore does not require a heart-lung bypass machine. In addition to improving blood flow through the heart, the procedure may also relieve symptoms such as fatigue and shortness of breath that often affect patients with significant MR. After treatment, patients generally recover quickly. The MitraClip(R) device may improve quality of life and may help MR patients avoid or delay surgery, having preserved surgical options (valve repair or replacement) should surgery become necessary.

About Evalve, Inc.

Founded in 1999, Evalve, Inc., headquartered in Menlo Park, Calif., has developed a proprietary system which enables percutaneous repair of cardiac valves. The company's initial products are intended to reduce the risks, trauma and costs associated with current open, arrested heart surgical options. For more information about Evalve, Inc., and for an animated explanation of the procedure using the MitraClip(R) device, visit www.evalveinc.com. Evalve is the first portfolio company from the medical device company incubator, The Foundry (www.thefoundry.com).

The MitraClip(R) system is currently undergoing clinical evaluation in the United States and Canada. The MitraClip(R) system is available for commercial distribution in the European Union.

MitraClip(R) and Evalve are registered trademarks of Evalve, Inc.


'/>"/>
SOURCE Evalve, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Social Security Administration First to Go Live With CONNECT Solution for Nationwide Health Information Network
2. Video: New First Response(R) Fertility Test Helps Women Answer the Question: Am I Able to Get Pregnant?
3. Imagine No More Waits for Emergency Room Care ... InQuickER Chooses Trevelino/Keller Communications to Launch First Service of Its Kind
4. I-Therapeutix Announces First Commercial Use of I-ZIP(R) Adherent Ocular Bandage for Clear Corneal Cataract Incisions
5. First Patients Treated in India Using CyberKnife Radiosurgery
6. Zimmer Holdings Announces Live Audio Webcast and Conference Call of First Quarter 2009 Results
7. World-first high blood pressure treatment trialled in Melbourne
8. Covance Inc. Invites You to Join the Webcast of Its First Quarter 2009 Financial Results Conference Call
9. Berlin Heart Receives First Regulatory Approval in North America
10. NIH releases the first research plan to reduce the burden of digestive diseases
11. LodgeNet Healthcare Provides Industrys First Integrated High-Definition Interactive System for Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... Texas (PRWEB) , ... May 25, 2016 , ... The ... Myers Veterans Biomedical Technology Program to help provide veterans a pathway to employment and ... Executive, presented a $20,000 check to Nick Hallack, President and CEO of Medisend, parent ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... International University (FIU) Herbert Wertheim College of Medicine announced the AUA-FIU Global MD ... Degree and Global Health Certificate from AUA and a Certificate of Completion from ...
(Date:5/25/2016)... O'Fallon, MO (PRWEB) , ... May 25, 2016 , ... ... located in Woodlawn Plaza at 8618 Mexico Road, O’Fallon, MO 63366. He serves patients ... and cosmetic treatments . Dr. Schwarz’s success is reflected in the superior ...
(Date:5/25/2016)... ... May 25, 2016 , ... Today Omega Institute, a leading destination ... innovative workshops and training opportunities in the growing field of yoga therapy ... who are dealing with specific health issues—including injuries, illnesses, and temporary or chronic health ...
(Date:5/25/2016)... ... ... Cheryl Bowker of Bowker Insurance Group has been presented with one of ... McKenna ran one of Allstate’s most successful agencies for 48 years, but it was ... The award named for him is not given every year, but only when an ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 2016 Niederländische Chirurgen haben ... es Ärzten erlaubt, ihre Expertise weltweit zu teilen ... Live Streaming mit einer Instant-Messaging-Funktion und der Möglichkeit, ... in Europa, Afrika, Asien und den ... Plattform registriert. Information und Weiterbildung   ...
(Date:5/24/2016)... May 24, 2016 ARANZ Medical ... the healthcare sector, has been named the Coretex Hi-Tech Emerging ... 2016. Dr Bruce Davey , CEO of ... team.  It,s really good to be recognised for the work ... products are used in 35 countries around the world from ...
(Date:5/24/2016)... , May 24, 2016 ... doble terapia del mundo, introduce catéteres para la ... OrbusNeich, una compañía global especializada en el ... ha expandido su cartera incluyendo productos para tratar ... y Scoreflex™ PTA son los dispositivos de primera ...
Breaking Medicine Technology: